The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Open accessAbstract
Limited information exists on the pharmacokinetic (PK)-pharmacodynamic (PD) relationships of drugs against Mycobacterium tuberculosis . Our aim was to identify the PK-PD parameter that best describes the efficacy of rifampin on the basis of in vitro and PK properties. Consistent with 83.8% protein binding by equilibrium dialysis, the rifampin MIC for M. tuberculosis strain H37Rv rose from 0.1 in a serum-free system to 1.0 mg/ml when it was tested in the presence of 50% serum. In time-kill studies, rifampin exhibited area under the concentration-time curve (AUC)-dependent killing in vitro, with maximal killing seen on all days and with the potency increasing steadily over a 9-day exposure period. MIC and time-kill studies performed with intracellular organisms in a macrophage monolayer model yielded similar results. By use of a murine aerosol infection model with dose ranging and dose fractionation over 6 days, the PD parameter that best correlated with a reduction in bacterial counts was found to be AUC/MIC ( r 2 = 0.95), whereas the maximum concentration in serum/MIC ( r 2 = 0.86) and the time that the concentration remained above the MIC ( r 2 = 0.44) showed lesser degrees of correlation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Holford, N. H. G., & Sheiner, L. B. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106060-00002 · Cited by 1,143
Global Surveillance for Antituberculosis-Drug Resistance, 1994–1997
Pablos-Méndez, A., Raviglione, M. C., Laszlo, A., Binkin, N., Rieder, H. L., Bustreo, F., Cohn, D. L., Lambregts-van Weezenbeek, C. S. B., Kim, S. J., Chaulet, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382301 · Cited by 815
The Pharmacodynamics of β‐Lactams
Turnidge, J. D. (1998) · Clinical Infectious Diseases · doi:10.1086/514622 · Cited by 593
Hyatt, J. M., McKinnon, P. S., Zimmer, G. S., & Schentag, J. J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00005 · Cited by 374
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials
Burman, W. J., Gallicano, K., & Peloquin, C. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140050-00002 · Cited by 337
Role of individual drugs in the chemotherapy of tuberculosis.
Mitchison, D. A. (2000) · PubMed · Cited by 319
Craig, W. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321854 · Cited by 318
Andes, D., & Craig, W. A. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2375 · Cited by 254
Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model
Cynamon, M. H., Klemens, S. P., Sharpe, C. A., & Chase, S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1189 · Cited by 243
The Pharmacodynamics of Aminoglycosides
Lacy, M. K., Nicolau, D. P., Nightingale, & Quintiliani, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514620 · Cited by 231
Pharmacodynamics of Fluoroquinolones
Lode, H., Borner, K., & Koeppe, P. (1998) · Clinical Infectious Diseases · doi:10.1086/514623 · Cited by 220
Armitige, L. Y., Jagannath, C., Wanger, A. R., & Norris, S. J. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.767-778.2000 · Cited by 211
Carryn, S., Françoise Van Bambeke, A., Mingeot‐Leclercq, M., & Tulkens, P. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2095-2103.2002 · Cited by 132
Wiegeshaus, E. H., McMurray, D. N., Grover, A. A., Harding, G. E., & Smith, D. W. (1970) · PubMed · doi:10.1164/arrd.1970.102.3.422 · Cited by 117
Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis
Kelly, B. P., Furney, S. K., Jessen, M., & Orme, I. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2809 · Cited by 111
Pharmacodynamics of Macrolides, Azalides, and Streptogramins: Effect on Extracellular Pathogens
Carbón, C. (1998) · Clinical Infectious Diseases · doi:10.1086/514619 · Cited by 106
Pharmacological Issues in the Treatment of Tuberculosis
PELOQUIN, C. A. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb11374.x · Cited by 82
Rastogi, N., Blom-Potar, M.-C., & David, H. L. (1987) · Current Microbiology · doi:10.1007/bf01588176 · Cited by 61
Burman, W. J. (1997) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40137-5 · Cited by 32
Cited by
Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates
Via, L. E., Lin, P. L., Ray, S. M., Carrillo, J., Allen, S. S., Eum, S. Y., Taylor, K., Klein, E., Manjunatha, U., Gonzales, J., et al. (2008) · Infection and Immunity · doi:10.1128/iai.01515-07 · Cited by 664
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Dorman, S. E., Nahid, P., Kurbatova, E. V., Phillips, P. P. J., Bryant, K., Dooley, K. E., Engle, M., Goldberg, S. V., Phan, H. T. T., Hakim, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033400 · Cited by 539
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
Alsultan, A., & Peloquin, C. A. (2014) · Drugs · doi:10.1007/s40265-014-0222-8 · Cited by 444
Boeree, M. J., Heinrich, N., Aarnoutse, R., Diacon, A. H., Dawson, R., Rehal, S., Kibiki, G. S., Churchyard, G., Sanne, I., Ntinginya, N. E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30274-2 · Cited by 379
Alisjahbana, B., Sahiratmadja, E., Nelwan, E. J., Purwa, A. M., Ahmad, Y., Ottenhoff, T. H. M., Nelwan, R. H. H., Parwati, I., Meer, J. W. M. V. D., & Crevel, R. V. (2007) · Clinical Infectious Diseases · doi:10.1086/519841 · Cited by 374
Metadata
- Authors
- Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., & Balasubramanian, V.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-07
- Volume
- 47
- Issue
- 7
- Pages
- 2118-2124
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2120761149
- Cited by
- 335
- References
- 22
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.